VNDA— Vanda Pharmaceuticals Inc.

MaterialsBiotechnology$302M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Net product sales	$216.1M+8.7%	$198.8M+3.2%	$192.6M-24.3%	$254.4M
Total revenues	$216.1M+8.7%	$198.8M+3.2%	$192.6M-24.3%	$254.4M
Cost of goods sold excluding amortization	$13.0M+15.3%	$11.3M-23.5%	$14.8M-39.1%	$24.3M
Research and development	$109.3M+46.8%	$74.4M-3.1%	$76.8M-10.4%	$85.8M
Selling, general and administrative	$238.0M+62.5%	$146.4M+29.7%	$112.9M-17.3%	$136.5M
Intangible asset amortization	$7.0M-3.7%	$7.3M+248.0%	$2.1M+37.9%	$1.5M
Total operating expenses	$367.3M+53.4%	$239.4M+15.9%	$206.6M-16.7%	$248.1M
Loss from operations	-$151.2M-271.8%	-$40.7M-191.4%	-$14.0M-320.4%	$6.3M
Other income, net	$12.5M-29.4%	$17.7M-12.6%	$20.3M+308.2%	$5.0M
Income (loss) before income taxes	-$138.6M-504.9%	-$22.9M-461.6%	$6.3M-43.9%	$11.3M
Provision (benefit) for income taxes	$81.8M+2135.0%	-$4.0M-205.0%	$3.8M-23.8%	$5.0M
Net income (loss)	-$220.5M-1066.5%	-$18.9M-853.3%	$2.5M-60.0%	$6.3M
Basic (in dollars per share)	-$3.74-1033.3%	-$0.33-925.0%	$0.04-63.6%	$0.11
Diluted (in dollars per share)	-$3.74-1033.3%	-$0.33-925.0%	$0.04-63.6%	$0.11
Basic (in shares)	58.9M+1.3%	58.1M+1.3%	57.4M+1.6%	56.5M
Diluted (in shares)	58.9M+1.3%	58.1M+1.0%	57.6M+1.0%	57.0M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.